Guidance on the use of trastuzumab for the treatment of advanced breast cancer

  • Technology appraisal guidance
  • TA34
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence

The following documentation and opinion was made available to the appraisal committee:

  • Assessment report:

    • Prepared by The NHS Centre for Reviews and Dissemination: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumab and vinorelbine for breast cancer, February 2001

    • Prepared by The NHS Centre for Reviews and Dissemination: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumab for breast cancer, October 2001

  • Manufacturer/sponsor submissions:

    • Roche

  • Professional/specialist group submissions from:

    • British Psychosocial Oncology Society

    • Imperial Cancer Research Fund

    • MRC Clinical Trials Unit

    • National Cancer Research Institute

    • Royal College of General Practitioners

    • Royal College of Pathologists

    • Royal College of Physicians

  • Patient group submissions from:

    • Breakthrough Breast Cancer, CancerBACUP and the UK Breast Cancer Coalition joint submission

    • Breast Cancer Care

    • Macmillan Cancer Relief

  • Other group submissions from:

    • Department of Health

    • National Assembly for Wales

  • External expert and patient advocate submissions from:

    • Professor Robert Coleman, Professor of Medical Oncology, Cancer Research Centre,Weston Park Hospital, University of Sheffield

    • Bernie Gardiner, Information Nurse Specialist, Breast Cancer Care

    • Margaret King, Vice Chair, UK Breast Cancer Coalition.